Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2018ASTELLAS PHARMA : Announces Launch of Dafclir® Tablets for the Treatment of Infe..
PU
2018ASTELLAS PHARMA : Gene Therapy Research Institution and Astellas Executes Option..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018ASTELLAS PHARMA : Pfizer and Astellas Amend Clinical Research Protocols for Two ..
PU
2018Pfizer, Astellas revise two cancer drug trial protocols to speed up results
RE
2018ASTELLAS PHARMA : Approval of Linzess® Tablets 0.25 mg in Japan for Additional I..
PU
2018ASTELLAS PHARMA : Announces Acquisition of Quethera - Acquisition furthers ' com..
PU
2018ASTELLAS PHARMA : Application for Supplemental Indication Filed for Hypercholest..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018ASTELLAS PHARMA : U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of ..
PU
2018ASTELLAS PHARMA : Received Approval for Dafclir® Tablets for the Treatment of In..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018ASTELLAS PHARMA : Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalut..
PU
2018ASTELLAS PHARMA : Named to FTSE4Good Index Series for the Seventh Consecutive Ye..
PU
2018ASTELLAS PHARMA : Announces Launch of XTANDI® Tablets in Japan for the Treatment..
PU
2018ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
PU
2018ASTELLAS PHARMA : Announces Personnel Change
PU
2018ASTELLAS PHARMA : Oncology C3 Prize® Returns for Third Year with Focus on Improv..
PU
2018ASTELLAS PHARMA : and FibroGen Announce Topline Results from Double-Blind Japan ..
PU
2018ASTELLAS PHARMA : Submits Application for Approval of Peficitinib for Rheumatoid..
PU
2018ASTELLAS PHARMA : Announces Acquisition of Own Shares
PU
2018ASTELLAS PHARMA : U.S. FDA Grants Priority Review to Astellas' New Drug Applicat..
PU
2018ASTELLAS PHARMA : Reports Financial Results for FY2017
BU
2018ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2018ASTELLAS PHARMA : Launches Global Campaign in Collaboration with CNN as Part of ..
PU
2018ASTELLAS PHARMA : Acquires Universal Cells, Inc. (pdf 178KB)
PU
2018ASTELLAS PHARMA : Partners with Discovery Communications for its Global Branding..
PU
2018ASTELLAS PHARMA : Announce Top-Line Results for Two Phase 3 Trials of Peficitini..
PU
2018ASTELLAS PHARMA : Announces Changes in Management Structure, Global Function, an..
PU
2018ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes (pdf 30..
PU
2018ASTELLAS PHARMA : Announces Transition to a Company with an Audit & Supervisory ..
PU
2018ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 119KB)
PU
2018ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017 ..
PU
2018ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017
BU
2018ASTELLAS PHARMA : Completes Acquisition of Mitobridge, Inc. (pdf 242KB)
PU
2018ASTELLAS PHARMA : Receives Orphan Designation from the European Commission for G..
PU
2018ASTELLAS PHARMA : and Vical Announce Top-Line Results for Phase 3 Trial of Cytom..
PU
2018ASTELLAS PHARMA : Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan..
PU
2018ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2018ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
PU
2017ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference (pdf 178KB)
PU
2017ASTELLAS PHARMA : Announces First Clinical Data from Phase I Study of Gilteritin..
PU
2017ASTELLAS PHARMA : the Institute of Medical Science of the University of Tokyo, C..
PU
2017ASTELLAS PHARMA : Announces Personnel Change(pdf 155KB)
PU
2017ASTELLAS PHARMA : Acquires Mitobridge Under Existing Collaboration(pdf 359KB)
PU
2017ASTELLAS PHARMA : Submits a New Drug Application for Gonax® 12-Week Extended-Rel..
PU
2017ASTELLAS PHARMA : to Present New Data Exploring Gilteritinib in Newly Diagnosed ..
PU
2017ASTELLAS PHARMA : MSD and Astellas conclude co-promotion agreement in Japan for ..
PU
2017ASTELLAS PHARMA : and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Ved..
PU
2017ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 121KB)
PU
2017ASTELLAS PHARMA : Reports First Half FY2017 Financial Results, Revises Fiscal Ye..
BU
2017ASTELLAS PHARMA : Positive Topline Results from First Japan Phase 3 Trial for Ro..
PU
2017ASTELLAS PHARMA : Reports First Half FY2017 Financial Results, Revises Fiscal Ye..
PU
2017ASTELLAS PHARMA : Partners with CNBC for its Global Branding Campaign (pdf 409KB..
PU
2017ASTELLAS PHARMA : Enters into a Screening Collaboration Agreement with MMV to Di..
PU
2017ASTELLAS PHARMA : Extension of Agreement Pertaining to Sale of Telmisartan (Mica..
PU
2017ASTELLAS PHARMA : and Universal Cells, Inc. Announce a Collaboration Utilizing U..
PU
2017ASTELLAS PHARMA : Enters into a New Collaborative Research Agreement with TB All..
PU
2017ASTELLAS PHARMA : U.S. FDA Grants Fast Track Designation to Astellas for Develop..
PU
2017ASTELLAS PHARMA : and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedo..
PU
2017ASTELLAS PHARMA : Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct "JOINUS,"..
PU
2017ASTELLAS PHARMA : and TOA EIYO Announce Co-promotion Agreement for Kiklin® Capsu..
PU
2017ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 311KB)
PU
2017ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2017ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
PU
2017ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2017ASTELLAS PHARMA : Astella Announces Status of Acquisition of Own Shares (pdf 311..
PU
2017ASTELLAS PHARMA : Repatha@ Receives Approval for New 420mg Single-Dose Delivery ..
PU
2017ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes(..
PU
2017ASTELLAS PHARMA : First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteri..
PU
2017ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 329KB)
PU
2017ASTELLAS PHARMA : LTL Pharma Succeeds Marketing Approval for "Nivadil® Tablets",..
PU
2017ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 310KB)
PU
2017ASTELLAS PHARMA : Reports First Quarter FY2017 Financial Results (pdf 434KB)
PU
2017ASTELLAS PHARMA : Reports First Quarter FY2017 Financial Results
BU
Prev.1  2   3  4  5  6  7  8Next
Upcoming event on ASTELLAS PHARMA INC.